Last reviewed · How we verify
Bronchodilators inhalation
Bronchodilators relax airway smooth muscle to widen airways and improve airflow to the lungs.
Bronchodilators relax airway smooth muscle to widen airways and improve airflow to the lungs. Used for Asthma, Chronic obstructive pulmonary disease (COPD), Reversible airway obstruction.
At a glance
| Generic name | Bronchodilators inhalation |
|---|---|
| Also known as | Salmeterol/fluticasone (Seretide Evohaler), fenoterol (Berotec)(0.1mg/puff) |
| Sponsor | Dr. J. Alberto Neder |
| Drug class | Bronchodilator (inhalation) |
| Target | Beta-2 adrenergic receptor or muscarinic receptor (class-dependent) |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Mechanism of action
Bronchodilators work by stimulating beta-2 adrenergic receptors (beta-agonists) or blocking muscarinic receptors (anticholinergics) on airway smooth muscle, causing relaxation and bronchodilation. This reduces airway resistance and improves ventilation, making breathing easier for patients with obstructive airway diseases.
Approved indications
- Asthma
- Chronic obstructive pulmonary disease (COPD)
- Reversible airway obstruction
Common side effects
- Tremor
- Tachycardia
- Headache
- Nervousness
- Palpitations
Key clinical trials
- Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis (PHASE1, PHASE2)
- Safety and Efficacy of Inhaled BMD003 (CFTR mRNA) in Chinese Cystic Fibrosis Patients Aged ≥12 Years (EARLY_PHASE1)
- A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital System (eMDPI DS) in Participants13 Years or Older With Asthma (PHASE4)
- Daratumumab in STK11 Mutated NSCLC (PHASE2)
- The Effect of NAC on Lung Function and CT Mucus Score (PHASE4)
- Impact of Inhaled PT003 on Complexity and Variability of Tidal Breathing and Oscillatory Mechanics in Stable COPD Patient (PHASE2)
- Effects of Inhaled Epinephrine on Systemic Allergic Reactions During Allergy Testing, Immunotherapy or Oral Challenges (PHASE1)
- Digital Physiotherapy for Pediatric Chronic Suppurative Lung Diseases (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |